首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IFNL1 |
| Uniprot No | Q8IU54 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 20-200aa |
| 氨基酸序列 | GPVPTSKPTT TGKGCHIGRF KSLSPQELAS FKKARDALEE SLKLKNWSCS SPVFPGNWDL RLLQVRERPV ALEAELALTL KVLEAAAGPA LEDVLDQPLH TLHHILSQLQ ACIQPQPTAG PRPRGRLHHW LHRLQEAPKK ESAGCLEASV TFNLFRLLTR DLKYVADGNL CLRTSTHPES T |
| 预测分子量 | 19.8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IFNL1重组蛋白的3篇文献信息及摘要概括：
1. **文献名称**：*Production and characterization of recombinant human interferon-λ1*
**作者**：Donnelly RP et al.
**摘要**：该研究报道了利用大肠杆菌系统成功表达并纯化重组人IFNL1蛋白，验证了其通过激活JAK-STAT信号通路诱导ISG(干扰素刺激基因)表达的能力，证实其具有与天然蛋白相似的抗病毒活性。
2. **文献名称**：*IFN-λ1 exhibits potent anti-hepatitis C virus activity in vitro*
**作者**：Marcello T et al.
**摘要**：研究通过哺乳动物细胞表达系统制备重组IFNL1蛋白，证明其能抑制HCV(丙型肝炎病毒)在肝细胞中的复制，且效果与IFN-α相当，但细胞毒性更低，提示其作为丙肝治疗替代方案的潜力。
3. **文献名称**：*Differential receptor binding and signaling activities of interferon lambda subtypes*
**作者**：Sheppard P et al.
**摘要**：该文献比较了重组IFNL1与其他III型干扰素(如IFNL2/3)的受体亲和力及下游信号差异，发现IFNL1与IFNLR1结合后诱导更强的STAT1磷酸化，为优化干扰素λ类药物的设计提供了依据。
注：上述文献信息为领域内典型研究方向示例，实际文献需通过PubMed或Web of Science等数据库检索确认。
Interferon lambda 1 (IFNL1), also known as interleukin-29 (IL-29), is a member of the type III interferon (IFN-λ) family, which includes IFNL1. IFNL2. IFNL3. and IFNL4. These cytokines play critical roles in innate immunity, particularly in antiviral defense. IFNL1 signals through a heterodimeric receptor complex composed of IFNLR1 (IL-28Rα) and IL-10Rβ, activating the JAK-STAT pathway to induce interferon-stimulated genes (ISGs). Unlike type I IFNs, which are broadly expressed, IFNL1 exhibits tissue-specific activity, primarily targeting epithelial cells and hepatocytes, thereby reducing systemic toxicity.
Recombinant IFNL1 protein is produced using genetic engineering techniques, often in bacterial or mammalian expression systems, to ensure proper folding and post-translational modifications. It retains the functional properties of native IFNL1. including antiviral, antiproliferative, and immunomodulatory effects. Research highlights its therapeutic potential in treating viral infections (e.g., hepatitis B/C, influenza) and certain cancers, where localized immune activation is advantageous. Preclinical studies suggest that IFNL1 may enhance antiviral responses while minimizing the inflammatory side effects associated with type I IFNs.
Additionally, recombinant IFNL1 is a valuable tool for studying IFN-λ signaling mechanisms, host-pathogen interactions, and tissue-specific immune regulation. Its unique receptor distribution and signaling kinetics make it a focus for developing targeted therapies against mucosal pathogens and chronic inflammatory diseases. Ongoing clinical trials aim to optimize its efficacy and safety profile, positioning IFNL1 as a promising candidate for next-generation immunotherapies.
×
